Skip to main
CGTX

Cognition Therapeutics (CGTX) Stock Forecast & Price Target

Cognition Therapeutics (CGTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cognition Therapeutics Inc. has seen a significant year-to-date increase of approximately 90% in its stock value, outperforming the XBI benchmark, while maintaining an appealing valuation with an enterprise value of under $90 million. The promising preclinical and clinical data for its lead product candidate, CT1812 (zervimesine), including a notable 82% reduction in neuropsychiatric inventory and improved caregiver distress outcomes, underscores its potential to effectively address age-related degenerative diseases. Additionally, the drug's advantageous pharmacological profile, which enables effective blood-brain barrier penetration and may offer a more tolerable treatment alternative compared to existing therapies, reinforces a robust outlook for Cognition Therapeutics as investor interest grows.

Bears say

Cognition Therapeutics Inc faces significant financial risks that contribute to a negative outlook, particularly related to its product candidate CT1812. Key risks include potential negative clinical data outcomes, delays in advancing CT1812 to pivotal trials, and challenges in securing regulatory approval, any of which may lead to downward revisions in financial estimates. Additionally, competition from other therapies and the possibility of medium-term dilution further complicate the company's commercial prospects and overall market positioning.

Cognition Therapeutics (CGTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cognition Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cognition Therapeutics (CGTX) Forecast

Analysts have given Cognition Therapeutics (CGTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cognition Therapeutics (CGTX) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cognition Therapeutics (CGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.